文献速递鼻科头颈外科

EGPA伴鼻息肉慢性鼻窦炎:美泊利单抗剂量与内镜鼻窦手术作用的真实世界多维分析

Chronic Rhinosinusitis With Nasal Polyposis in EGPA: A Real-Life Multidimensional Analysis Through Mepolizumab Dosing and Role of Adjunctive Endoscopic Sinus Surgery (ESS).
PubMed 文献 · Int Forum Allergy Rhinol · 2026-05-13

本研究回顾性分析52例接受美泊利单抗治疗并随访24个月的EGPA伴鼻息肉患者,采用NPS、LKS、LMK和SNOT-22评估鼻窦结局,BVAS评估全身活动。结果显示全身缓解率>90%且嗜酸性粒细胞显著抑制,但鼻息肉和黏膜病变持续存在;基线鼻窦负荷高、手术史广泛及美泊利单抗剂量变化与辅助ESS相关。

要点

  • 美泊利单抗治疗下全身缓解率高,但鼻窦病变持续,需独立评估。
  • 持续100mg方案显示最大内镜下改善。
  • 基线鼻窦负荷高和剂量变化与辅助ESS相关。

核心结论

  • EGPA患者接受美泊利单抗治疗虽达全身缓解,鼻窦疾病仍可能持续,提示存在部分独立的炎症微环境。
  • 管理慢性结构性病变可能需要生物制剂与手术整合策略。

研究设计与样本

  • 回顾性分析52例EGPA伴鼻息肉患者,随访24个月的美泊利单抗治疗。
  • 鼻窦疾病采用NPS、LKS、LMK和SNOT-22评估,全身活动采用BVAS评估。
  • 患者按美泊利单抗方案分层(100 mg、300 mg和降阶梯),通过多变量逻辑回归探索辅助ESS的预测因素。

主要发现

  • 全身缓解发生于>90%的患者,嗜酸性粒细胞中位数从700降至59.5 cells/µL,BVAS=0。
  • NPS和LKS保持稳定:NPS 4 [3-5] → 4 [2-5];LKS 6 [4-8] → 5 [2-7.75]。
  • 64%的患者息肉持续存在,92%的患者黏膜水肿/分泌物持续存在。
  • 持续100 mg治疗显示最大的内镜下改善。
  • 辅助ESS发生率为28.8%,与基线鼻窦负荷高、手术史更广泛及美泊利单抗剂量变化相关,而BVAS和嗜酸性粒细胞与ENT严重程度无相关性。

关键数值与推荐

  • 全身缓解定义为>90%的患者达到缓解,BVAS=0。
  • 嗜酸性粒细胞中位数从700 cells/µL降至59.5 cells/µL。
  • NPS中位数从4 [3-5]变为4 [2-5],LKS中位数从6 [4-8]变为5 [2-7.75]。
  • 息肉持续存在率64%,黏膜水肿/分泌物持续存在率92%。
  • 辅助ESS发生率28.8%。

临床怎么用

  • 对EGPA伴鼻息肉患者,即使全身缓解,仍需专门耳鼻咽喉科评估鼻窦疾病。
  • 综合评估应结合全身标志物与耳鼻咽喉专科检查。
  • 对于慢性结构性病变,可考虑生物制剂与手术整合管理。

局限性

  • 回顾性研究设计。
  • 样本量较小(52例)。
  • 随访时间24个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare necrotizing vasculitis involving upper- and lower-airways. Despite biologics, sinonasal disease often persists. Evidence on ENT trajectories under anti-IL5 treatment and role of endoscopic sinus surgery (ESS) remains limited and is often described without standardized assessment tools. This study provides a systematic, multidimensional evaluation of sinonasal outcomes under biologic therapy and analyzes the role of ESS in a real-life cohort. METHODS: We retrospectively analyzed 52 EGPA patients with a 24-month follow-up on mepolizumab. Sinonasal disease was assessed by Nasal Polyp Score (NPS), Lund-Kennedy Score (LKS), Lund-Mackay score (LMK), and SNOT-22, while systemic activity was assessed by Birmingham Vasculitis Activity Score (BVAS). Patients were stratified by mepolizumab regimen (100 mg, 300 mg, and step-down). Predictors of adjunctive ESS were explored through multivariate logistic regression. RESULTS: Systemic remission occurred in >90% of patients, with marked eosinophil suppression (median 700 → 59.5 cells/µL) and BVAS = 0. Conversely, NPS and LKS remained stable [IQR]: (NPS 4 [3-5] → 4 [2-5]; LKS 6 [4-8] → 5 [2-7.75]. Polyps persisted in 64% and mucosal edema/discharge in 92% of population. Continuous 100 mg therapy showed the greatest endoscopic improvement. Higher baseline sinonasal burden, more extensive surgical history, and mepolizumab dose variation were associated with adjunctive ESS (28.8%), whereas BVAS and eosinophils showed no correlation with ENT severity. CONCLUSION: Sinonasal disease may persist despite systemic remission, suggesting a partially independent inflammatory niche. Comprehensive assessment should combine systemic markers with dedicated ENT evaluation, while management may require integrated biologic-surgical strategies in chronic structural disease.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Howardson BO, Danè G, Moroni L, et al. Chronic Rhinosinusitis With Nasal Polyposis in EGPA: A Real-Life Multidimensional Analysis Through Mepolizumab Dosing and Role of Adjunctive Endoscopic Sinus Surgery (ESS). Int Forum Allergy Rhinol. 2026. PMID: 42838758. doi:10.1002/alr.70184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。